Curiox Biosystems and Calebio Announce Strategic Partnership to Advance Automation in Flow Cytometry Across China

Exclusive Distribution Agreement Signed for Pluto Workstations to Expand Full-Spectrum Flow Cytometry Integration

SEOUL, Korea/ Nanjing, China April 29, 2025 — Curiox Biosystems Co. Ltd, global leader in automated sample preparation for flow cytometry and single-cell analysis, today announced the signing of an exclusive distribution agreement with Calebio, a pioneering developer of full-spectrum flow cytometers based in Nanjing, China. Under the multi-year agreement, Calebio will serve as the exclusive distributor of Curiox’s Pluto Workstation platform in mainland China (excluding the North China region), marking a major milestone in Curiox’s expansion into one of the fastest-growing biotech markets in the world.

As part of the strategic agreement, Calebio has committed to a minimum number of unit purchases through 2027, starting with the recent acquisition of Pluto Workstation demo systems. The rollout will support broader deployment across hospitals, research institutes, and biotech companies throughout the country.

“We are excited to partner with Calebio, a company with a deep understanding of the Chinese biotech market and strong commercial capabilities,” said a Curiox China executive. “This partnership marks a major milestone for the Pluto Workstation’s expansion into China, and we look forward to achieving significant market growth together.”

Bundling for Full-Spectrum Cell Analysis: An Integrated Solution

Calebio, recognized as the first domestic innovator of full-spectrum flow cytometry in China, brings a powerful portfolio of 4-laser systems and a leadership team with extensive experience from firms like GE and Agilent. Their vision aligns closely with Curiox’s mission to simplify and standardize cell sample preparation workflows through automation.

Together, the companies aim to deliver a bundled offering: combining Calebio’s flow cytometry instrumentation with Curiox’s Pluto Workstations, powered by C-FREE™ technology, which replaces traditional centrifuge-based washing steps. This integration enables consistent sample quality, eliminates manual variability, and boosts reproducibility—factors critical to high-content immunophenotyping, CAR-T monitoring, and multiplex cytokine assays.

Automation, Reproducibility, and Productivity: Pluto’s Value Proposition

Flow cytometry is increasingly relied upon for high-content cellular analysis, yet the field continues to face challenges with variability, labor intensity, and reproducibility—especially in sample preparation. The Pluto Workstation directly addresses these challenges by automating the upstream steps of flow cytometry workflows, traditionally dependent on centrifuge-based techniques. This automation minimizes operator-dependent variability, improves consistency across sites, and enhances the overall interpretability of downstream data.

In China, where demand for full-spectrum and high-parameter analysis is rapidly accelerating, these attributes are especially critical. The Pluto platform’s ability to standardize complex multi-step assays enables Calebio to offer a robust, bundled solution to its academic and industrial customers.

Under the terms of the exclusive agreement, Calebio has committed to a baseline number of Pluto Workstation unit purchases through 2027. Deployment has already begun with recently acquired demo systems, with expansion planned across China (excluding North China regions). This structure reflects confidence in the long-term strategic fit of Pluto automation within Calebio’s commercial roadmap and its alignment with national priorities for biotech self-sufficiency and innovation.

About Calebio

Calebio is a leading Chinese biotechnology company focused on full-spectrum flow cytometry technology. Its instruments enable researchers to collect high-dimensional fluorescence data across the full light spectrum, supporting the next generation of cell biology, immunology, and therapeutic discovery efforts in China.

About Curiox Biosystems Co. Ltd

Curiox Biosystems Co. Ltd is a global biotechnology firm advancing life sciences through innovative sample preparation technologies. With proprietary C-FREE™ technology, the company enables reproducible, automated workflows that minimize variability and manual errors—accelerating therapeutic discovery and development. Headquartered in Seoul, with offices in the U.S. and China, Curiox serves leading pharmaceutical companies, research institutions, and clinical labs worldwide.

For more information, visit https://www.curiox.com/ or contact:

For Curiox Biosystems Co. Ltd:
USA: 400 W Cummings Park #6650, Woburn, MA 01801
Corporate office
#212 Samsung Harrington IT Tower, 9 Gil 41 Digital-Ro, Geumchun-Gu, Seoul 08511, Korea

Please find the original press release here.